Neobiotech company, Cyclica recently announced that it has raised CAD$23mn in Series B funding round. The funding round was led by Drive Capital with participation from Chiesi Farmaceutici, GreenSky Capital, and members of Cyclica’s management team. With the new funding, the company will support continued innovation around Cyclica’s integrated proteome-wide drug discovery platform, and will…